JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Acute Respiratory Infections in Global Outpatient Setting

Early Phase 1

Completed

Conditions: Acute Respiratory Infection

Interventions: Diagnostic Test: Nasal Swab Sample

First Posted Date: 2021-12-08

Last Posted Date: 2024-08-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 245

Registration Number: NCT05148780

Locations: 🇺🇸
Harrisburg Family Medical Center, Harrisburg, Arkansas, United States
🇺🇸
Innovative Research of West Florida, Incorporated, Clearwater, Florida, United States
🇺🇸
New Life Medical Research Center, Inc., Hialeah, Florida, United States

and more 67 locations

A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection

Phase 1

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: JNJ-73763989
Biological: JNJ-64300535
Drug: ETV monohydrate
Drug: Tenofovir disoproxil
Drug: TAF

First Posted Date: 2021-11-17

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 24

Registration Number: NCT05123599

Locations: 🇮🇹
Irccs Ospedale Maggiore Di Milano, Milano, Italy
🇳🇿
New Zealand Clinical Research, Auckland, New Zealand
🇵🇱
ID Clinic, Myslowice, Poland

and more 10 locations

A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)

Phase 1

Completed

Conditions: Healthy
Hepatic Impairment

Interventions: Drug: Lazertinib

First Posted Date: 2021-11-09

Last Posted Date: 2023-10-12

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 16

Registration Number: NCT05112952

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇩🇪
APEX GmbH, Munchen, Germany

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: RPV LA
Drug: CAB LA

First Posted Date: 2021-11-09

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 126

Registration Number: NCT05112939

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant

Terminated

Conditions: Depressive Disorder, Major

Interventions: Other: Standard of Care (SOC)

First Posted Date: 2021-11-05

Last Posted Date: 2023-11-08

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 7

Registration Number: NCT05109195

Locations: 🇺🇸
The University of Pittsburgh of the Commonwealth System of Higher Education, Pittsburgh, Pennsylvania, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇬🇧
Warneford Hospital, Oxford, United Kingdom

and more 1 locations

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

Phase 1

Completed

Conditions: Healthy Non-dependent, Recreational Sedative Users
Abuse Potential

Interventions: Drug: Suvorexant
Drug: Zolpidem
Drug: Placebo
Drug: Seltorexant

First Posted Date: 2021-11-03

Last Posted Date: 2024-06-21

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 127

Registration Number: NCT05106153

Locations: 🇺🇸
Altasciences Inc., Overland Park, Kansas, United States

A Long-term Extension Study of Ustekinumab in Pediatric Participants

Phase 3

Recruiting

Conditions: Colitis, Ulcerative
Crohn Disease
Arthritis, Psoriatic

Interventions: Drug: Ustekinumab

First Posted Date: 2021-10-25

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 151

Registration Number: NCT05092269

Locations: 🇦🇷
Centro de Investigaciones Medicas Tucuman, San Miguel De Tucuman, Argentina
🇧🇪
Huderf, Bruxelles, Belgium
🇧🇪
Cliniques Universitaires Saint Luc, Bruxelles, Belgium

and more 36 locations

A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis

Phase 1

Terminated

Conditions: Healthy
Arthritis, Psoriatic

Interventions: Drug: Guselkumab
Drug: Risankizumab

First Posted Date: 2021-10-19

Last Posted Date: 2022-07-26

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 11

Registration Number: NCT05083078

Locations: 🇦🇹
Medical University Graz, Graz, Austria

A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

Phase 3

Recruiting

Conditions: Arthritis, Juvenile

Interventions: Drug: Ustekinumab
Drug: Guselkumab

First Posted Date: 2021-10-19

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 48

Registration Number: NCT05083182

Locations: 🇩🇰
Aarhus Universitetshospital, Arhus, Denmark
🇩🇰
Odense Universitets Hospital, Odense, Denmark
🇫🇷
CHU de Caen, Caen, France

and more 43 locations

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Teclistamab
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Bortezomib

First Posted Date: 2021-10-19

Last Posted Date: 2025-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 587

Registration Number: NCT05083169

Locations: 🇺🇸
Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 176 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy